Occasional essay: upper motor neuron syndrome in amyotrophic lateral sclerosis by Swash, Michael et al.
The upper motor neuron syndrome in amyotrophic lateral 
sclerosis
Article  (Accepted Version)
http://sro.sussex.ac.uk
Swash, Michael, Burke, David, Turner, Martin R, Grosskreutz, Julian, Leigh, P Nigel, de 
Carvalho, Mamede and Kiernan, Matthew C (2019) The upper motor neuron syndrome in 
amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery and Psychiatry. ISSN 0022-
3050 (Accepted) 
This version is available from Sussex Research Online: http://sro.sussex.ac.uk/id/eprint/89267/
This document is made available in accordance with publisher policies and may differ from the 
published  version or from the version of record. If you wish to cite this item you are advised to 
consult the publisher’s version. Please see the URL above for details on accessing the published 
version. 
Copyright and reuse: 
Sussex Research Online is a digital repository of the research output of the University.
Copyright and all moral rights to the version of the paper presented here belong to the individual 
author(s) and/or other copyright owners.  To the extent reasonable and practicable, the material 
made available in SRO has been checked for eligibility before being made available. 
Copies of full text items generally can be reproduced, displayed or performed and given to third 
parties in any format or medium for personal research or study, educational, or not-for-profit 
purposes without prior permission or charge, provided that the authors, title and full bibliographic 
details are credited, a hyperlink and/or URL is given for the original metadata page and the 
content is not changed in any way. 
 1 
The upper motor neuron syndrome in amyotrophic lateral sclerosis 
 
Michael Swash, David Burke, Martin R Turner, Julian Grosskreutz, P Nigel Leigh, Mamede 
de Carvalho and Matthew C Kiernan 
 
 
Affiliations: 
 
MS: Barts and the London School of Medicine, QMUL, London UK; and Instituto de 
Medicina Molecular, Faculdade de Medicina, Univeridade de Lisboa 
 
DB:  University of Sydney and Department of Neurology, Royal Prince Alfred Hospital, 
Sydney, NSW, Australia 
 
MRT: Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK 
 
MCK: University of Sydney and Department of Neurology, Royal Prince Alfred Hospital, 
Sydney, NSW, Australia 
 
PNL: Trafford Centre for Biomedical Research, Department of Neuroscience, Brighton and 
Sussex Medical School, University of Sussex, Brighton UK 
 
JG: Universitätsklinikum Jena, Friedrich-Schiller-University Jena, Jena, Germany 
 
MdeC: Instituto de Fisiologia, Instituto de Medicina Molecular, Faculdade de Medicina, 
Univeridade de Lisboa, and Department of Neurosciences and Mental Health, Hospital de 
Santa Maria, Centro Hospitalar Universitário de Lisboa Norte. Lisbon, Portugal 
 
Funding acknowledgements: MCK receives funding support from the National Health and 
Medical Research Council of Australia Program Grant (#1132524), Partnership Project 
(#1153439) and Practitioner Fellowship (#1156093). PNL is supported by funding from:  The 
European Union H2020 Program (Grant No 633413); The MND Association; The Dunhill 
Trust; The Wellcome Trust. JG is supported by the Dt. Gesellschaft für Muskelkranke 
(DGM). 
 
 
Correspondence: mswash@btinternet.com 
Word count: 4474 
Abstract word count: 164 
References: 153  Tables: 1   Illustrations: 1 
 
  
 2 
 
Introduction 
 
The diagnosis of amyotrophic lateral sclerosis (ALS) requires recognition of both lower 
(LMN) and upper motor neuron (UMN) dysfunction.1 However, classical UMN signs are 
frequently difficult to identify in ALS.2 LMN involvement is  sensitively detected by 
electromyography (EMG)3 but, as yet, there are no generally accepted markers for monitoring 
UMN abnormalities,4  the neurobiology of ALS itself, and disease spread through the brain 
and spinal cord,.5 Full clinical assessment is therefore necessary to exclude other diagnoses 
and to monitor disease progression. In part, this difficulty regarding detection of UMN 
involvement in ALS derives from the definition of ‘the UMN syndrome’. Abnormalities of 
motor control in ALS require reformulation within an expanded concept of the UMN, 
together with the neuropathological, neuro-imaging and neurophysiological abnormalities in 
ALS. We review these issues here. 
 
The Lower Motor Neuron 
Sir Charles Sherrington (1857-1952) defined the LMN6,7 as the anterior horn cell and its 
motor axon, constituting the final common pathway for reflex action.8  In 1906 Sherrington,7 
following Hughlings Jackson’s insights, concluded that motor acts were initiated in the brain 
by sensory input, thus building on activation of this simple reflex pathway, a view further 
developed by Sir Francis Walshe (1885-1973).9  Merton et al10 likened the effect of reflex 
action to a follow-up length servo, an influential hypothesis, that was subsequently modified 
as servo assistance to emphasize that stretch reflexes support movement, generated centrally, 
rather than drive it.11,12 Despite these ideas, the UMN syndrome is not well defined.7,13-15 
 
The Upper Motor Neuron 
The clinical criteria (Table 1) used by generations of neurologists to define the ‘corticospinal’ 
or ‘pyramidal’ syndrome, a term frequently but erroneously regarded as synonymous with 
‘UMN syndrome’, rest on surprisingly uncertain pathophysiological underpinnings. The term 
UMN was introduced by Sir William Gowers (1845-1915) in his Manual of Neurology13 
published before Sherrington’s work.14 Later, the anatomist, Alf Brodal (1910-1988), 
emphasized that the UMN16 consists not just of corticospinal fibres but of all those fibres 
with motor functions that descend through the pyramids in the lower brainstem on each side. 
The UMNs therefore include crossed and uncrossed corticospinal tracts (CST), corticobulbar, 
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tectospinal, rubrospinal, vestibulospinal and reticulospinal tracts, as well as various short 
internuncials and cerebellar connexions.15-17 The CSTs constitute only 2-3% of fibres in the 
pyramidal UMN pathway.18 They provide direct connexions between Betz ‘giant’ cells in 
primary motor cortex and anterior horn cells in the anterior spinal grey matter and also, 
through corticobulbar connexions, to neurons in the bulbar motor nuclei. This corticospinal 
projection consists of large diameter (>10µm), thickly myelinated, monosynaptic, fast-
conducting motor efferents. However, most fibres passing caudally through the pyramids are 
much smaller, <4µm in diameter.9,18 The majority of fibres in the medullary pyramids have 
indirect, polysynaptic projections to spinal interneurons and motoneurons. In addition to the 
well-known monosynaptic corticomotoneuronal projection, in cat, macaque and humans 
corticospinal axons have disynaptic projections to upper-limb motoneuron pools through 
propriospinal neurons located in the C3-C4 levels. This relay allows the corticospinal 
command to be modulated before it reaches segmental level through a combination of 
feedback from the moving limb and feedforward inhibition from supraspinal centres. Within 
these diverse efferent motor projections there are additional descending fibres derived widely 
from the cerebral cortex, including sensory cortex, that also project to interneurons and 
primary motor neurons in the anterior horns of the cord, as well as to sensory neurons in the 
dorsal horn. These descending projections modulate both sensory input to the cord and its 
motor output.19 In summary, the grey matter of the spinal cord is a busy place and much of 
what goes on there is not under direct voluntary control. This is consistent with the semi-
automatic nature of rapid object grasping. As Lemon19 summarised: ‘the descending 
pathways function as part of a large network rather than as separate controllers of the spinal 
cord’ and ‘the spinal cord functions as part of the brain not as its servant’. The clinical terms 
“pyramidal syndrome” or “UMN syndrome” conceal a complex motor system.9,15 
 
The clinician’s corticospinal syndrome 
Hughlings Jackson20 made detailed studies of the clinical features of hemiplegia in stroke. He 
drew attention not only to negative features, such as loss of strength and orienting responses, 
but also to positive features, such as increased muscular tone, and a brisk knee jerk. The 
Babinski response was incorporated later (Table 1).21-23 In hemiplegia Jackson recognized 
residual, voluntary limb motor function and characteristic resting limb and body postures. For 
these and other reasons, especially those related to his observation of the ‘march of focal 
epilepsy’, he concluded that movements were represented in cerebral cortex and muscles in 
spinal segments, a view that remains generally accepted.24 Modern descriptions of lesions 
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ascribed to the pyramidal pathway emphasize weakness, loss of dexterity, slowness and 
poverty of hand movements, brisk tendon reflexes, a spastic increase in muscle tone and the 
extensor plantar response (Table 1). Spasticity and weakness do not necessarily coexist, and 
probably relate to dysfunction in different pathways. Denny-Brown and Botterell25 found that 
ablation of Brodmann cortical area 4 in the macaque led to flaccid hemiparesis, followed in a 
few days by increased tendon jerks and hypertonus of distal limb segments, whereas ablation 
of Brodmann area 6 caused a more widespread hypertonus resembling the clinician’s 
‘extrapyramidal rigidity’.25 However, in the macaque, Fulton described spasticity, 
hemiparesis and apraxia after area 6 ablation.26 Much therefore depends on the site and extent 
of any lesion in the motor system; and also on the ability of researchers to examine primates 
as fully as human subjects. Walshe9 reviewed these and earlier experiments, including early 
ablation studies in primates,27 and studies of electrical stimulation of the cerebral cortex in 
humans.28 He drew the important conclusions that cortical electrical stimulation was likely to 
be dependent on the characteristics of the stimulation technique, a factor difficult to 
quantify.9 
 
Tower29 found that section of the pyramid at the medullary level in monkey caused a ‘grave 
and general poverty of movement’ and initial hypotonia. Fine, discrete movements were lost 
and there was impairment of aim and precision of movement performance, i.e., poverty of 
movement with loss of dexterity. In the chimpanzee, but not in the monkey, a Babinski reflex 
could be elicited and there was increased proprioceptive grasping in the upper limb. In 
searching for methods to alleviate Parkinsonian tremor, Bucy30,31 surgically sectioned the 
human ipsilateral cerebral peduncle. There was less resultant paresis than anticipated and 
remarkable recovery occurred, but with persistent impairment of fine manipulative finger and 
hand movement. Electrical stimulation of the uninjured peduncle delineated a medial fronto-
pontine bundle, associated with hand and forearm movements, and a more lateral temporo-
pontine tract. Mid or upper cervical pyramidotomy, as reported by Lassek et al32 for surgical 
alleviation of tremor, caused paralysis below the site of the lesion that gradually improved, 
with considerable residual impairment of upper limb movements, weakness of foot 
dorsiflexion, increased tendon reflexes and a Babinski response.32  
 
The functions of the complex motor pathways at brainstem level were addressed by 
Lawrence and Kuypers in their now-classic primate experiments.33-35 After bilateral 
pyramidotomy at olivopontine level that interrupted the corticospinal pathway from cortical 
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area 4, climbing behaviour, as an example of whole body movement, was largely intact, but 
there was impaired speed and fluency. There was loss of dexterity of hands and digits in 
retrieving food rewards and isolated actions, such as reaching and grasping, were also 
severely and permanently affected. Subsequent interruption of the ventromedial descending 
motor pathway in the medial reticular formation in the floor of the fourth ventricle, consisting 
of descending fibres from the tectum, the pontine and medullary medial reticular formation 
and the vestibular complex, caused loss of righting responses, impaired unsupported sitting, 
walking and climbing and of head, shoulder and trunk movement, but without loss of 
automatic hand grasping. Lesion of the magnocellular rubrospinal fibres in the lateral 
medullary brainstem pathway that project to the dorso-lateral zones of the spinal anterior 
horns, caused loss of ipsilateral hand movements, with a persistent posture of flexion of the 
arm and extension of the fingers. Bilateral pontine lesions caused similar abnormalities.  
 
Lawrence and Kuypers’ work confirmed that the brain motor system consists of much more 
than the CST and the primary motor cortex.33,34 They concluded that the ventromedial 
brainstem pathways are the basic system by which the brain controls bodily movement, 
maintenance of posture, and integration of body-limb movements and locomotion, while the 
lateral brainstem pathway confers the ability to superimpose independent movements of the 
extremities, especially the hand, and the corticospinal pathways facilitate further fractionation 
of movement, especially finger movements. The lateral CSTs project to the intermediate 
internuncial zone of ventral spinal grey matter, linked to motor neurons innervating muscles 
of the distal extremities. Corticospinal neurons originating in M1 project directly to these 
spinal motor neurons, and to the ventromedial intermediate zone controlling trunk and limb-
girdle muscles. In addition, some fibres in the CSTs originate in the primary somatosensory 
cortex and terminate in the spinal dorsal horn.  
Single corticomotoneurons and their pyramidal tract axons project to multiple muscles in the 
primate upper-limb, though usually with a stronger projection to one muscle – stronger and 
more widespread to extensor muscles than flexors, and stronger distally  than proximally.36 
There may be plasticity at the corticomotoneuronal synapse, since connectivity is altered by  
movement in primates,,37 and segmental interneurons are active during voluntary movement38  
 
As in the cat,39 and the macaque,40 in human subjects the CST projects to upper cervical 
propriospinal neurons which then relay some of the corticospinal command to upper limb 
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motor neurons.41,42 This allows updating of the motor command by sensory feedback from the 
moving limb.43 There seem to be no such projections to the intrinsic muscles of the hand.  
 
The UMN deficit in ALS 
The UMN features (Table 1) in ALS are not typical of the classic UMN syndrome (Table 1). 
For example, the plantar responses may be downgoing, even in the presence of other classical 
UMN features.2 UMN lesions cause loss of the local extensor reflexes, such as the plantar 
reflex response, and also the abdominal and cremasteric reflexes, and disinhibition of the 
flexion withdrawal response, manifested by activation of extensor hallucis longus and 
therefore a dorsiflexor (extensor) Babinski toe response,44 but this will depend on the force 
exerted by these opposing reflex systems, which may be disrupted by the motor network 
disorder in ALS.   In In ALS there is widespread involvement of the UMN2 beyond the 
archetypal corticospinal lesion familiar from internal capsular infarction.16,20 Attribution of 
components of the motor syndrome in ALS specifically to UMN or LMN dysfunction is 
difficult since both are usually present. LMN features often predominate and spasticity and 
increased reflexes may be subtle.2 The progressive pattern of LMN weakness and atrophy in 
ALS suggests relatively orderly spread from a clinical site of origin,45 perhaps representing 
spread by contiguity in spinal segments,46,47 but ‘skip lesion’ weakness and atrophy also 
occur,48,49 and a CNS origin for these phenomena has been proposed.50  
 
Kinnier Wilson51 taught that flexor muscles are earlier and more severely affected than 
extensors, although long extensors of the forearm are weakened before long flexors. In the 
hand the abductor pollicis brevis and first dorsal interroseous muscles are particularly 
susceptible but the abductor digiti minimi is relatively spared. This ‘split hand’52 has been 
linked to the dense corticospinal innervation of the more susceptible  muscles53 associated 
with their importance in thumb movement and grasping,50 but this pattern of wasting is 
inconstant and other, perhaps related, explanations are possible.54  The motor syndrome in 
ALS includes abnormalities of stance and balance, and of foot placement, sometimes with 
features consistent with loss of orienting reflexes.55 Hand and finger movement is often 
markedly affected, with loss of dexterity and slowness of movement, sometimes described as 
clumsiness, in addition to objective weakness of grasp and other hand and finger movements. 
The gait is also clumsy and unreactive to barriers, as in managing ambulation over a rough 
surface. When there is bulbar involvement the normal precise coordination of respiratory 
pattern, voice, speech, swallowing, saliva management, and facial movement is impaired 
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causing degradation and coarseness of all these functions. These deficits result from 
degeneration of small-fibre propriospinal rather than corticospinal motor pathways and their 
central network connections, as shown by the Lawrence and Kuypers experiments described 
above. 
 
Higher-order functional motor deficits in ALS 
Loss of dexterity is a well-recognised feature of the “UMN syndrome” in stroke.56 When the 
corticospinal tract is damaged, recovery of the function of intrinsic muscles of the hand is 
less reliant on oligosynaptic corticospinal and other descending inputs, because they are the 
only upper-limb muscles to receive an exclusively monosynaptic (and lateralised) 
corticospinal input.42 In his textbook Kinnier Wilson commented on prominent  
‘awkwardness of fine finger movements’ in the early stages of ALS, despite only slight 
weakness and the absence of spasticity.51  This forgotten observation  suggests a higher-order 
motor defect, or  apraxia, associated with frontotemporal cortical atrophy and the associated 
tract degeneration that characterize the CNS disorder in ALS and ALS-FTLD. Higher-order 
motor deficits are particularly evident in behavioural variant FTLD, manifest by motor 
slowness and loss of intuitive, complex patterns of voluntary movement, and dominated by a 
prominent frontal executive syndrome with frontal and prefrontal cortical atrophy, with or 
without an associated ALS syndrome.  
 
The term apraxia has not been applied to the motor disorder in ALS perhaps because this 
extends the concept of apraxia beyond its classical definition as a higher-order motor disorder 
in the absence of focal neurological signs, especially weakness or sensory loss.57,58 However, 
in modern usage, apraxia, due to loss of specialised cortical function from focal lesion or 
degeneration, has been termed ‘hodological apraxia’, and disconnexion syndromes due to 
fibre tract degeneration, ‘topological apraxia’.59 Cortical and pathway lesions may induce 
increased or decreased excitability in the damaged motor system.59 Recognition of higher-
level motor disturbances in ALS extends understanding of the UMN or central motor 
dysfunction. ALS patients require marked effort to achieve adequate velocity and precision of 
movement, but retain ability to visualize and describe motor components necessary to 
perform fine graduated movements. Thus, the core features of ideomotor apraxia are absent, 
in ALS57,58 although they may be recognisable in ALS-FTLD. In ALS, the cortical disorder 
and secondary motor tract degeneration cause disconnexion of the cerebral motor systems 
from the spinal cord motor systems, including propriospinal motor connections and 
 8 
proprioceptive control mechanisms. Disruption and slowness of movement in ALS results 
both from degeneration in descending motor pathways and loss of control mechanisms; for 
example, connexions to basal ganglia and cerebellum that normally fine tune the motor drive.  
 
Neuropathology of the UMN in ALS 
Pathological studies of the CNS in ALS are inevitably limited to end-stage disease. The first 
descriptions of cellular pathology in the motor cortex and subcortical motor pathways derive 
from Marie who, with Charcot, described ‘atrophy of the large pyramidal cells of the cortex’, 
loss of these cells, and ‘numerous granular bodies’ in the subcortical white matter, interpreted 
as degenerating corticofugal fibres.60,61 Degeneration of corticofugal fibres was traced 
through the internal capsule into the cerebral peduncles, the medullary pyramids and spinal 
cord, but was not seen at a higher level,62-64 in contrast to the pattern of degeneration 
following vascular lesions of the motor cortex in which the process progressed caudally - a 
‘dying forward’ process.60 Marie therefore dismissed the notion that in ALS degeneration of 
the CST proceeds caudally from the motor cortex to the spinal cord, in parallel with loss of 
spinal motor neurons: “Unfortunately, gentlemen, this seductive theory very imperfectly 
explains the morbid process which produces amyotrophic lateral sclerosis and serious 
objections may be made to its adoption”.60 This puzzle remains unresolved’65 but is 
consistent with emerging concepts of ALS as a network connectivity disorder. 
 
There is variable loss of pyramidal neurons in ALS, particularly Betz cells, in the primary 
motor cortex and surrounding areas.63,64,66-69  but cerebral pathology is not solely restricted to 
the primary motor cortex.7,64 In ALS-FTLD syndromes there is marked frontal atrophy; with 
neuronal loss in layers 2, 3 and 5, ‘status spongiosus’, astrogliosis, and microglial 
proliferation as co-indicators of widespread pathology. At autopsy abnormalities in ALS are 
widespread in central motor pathways. REF Loss of pyramidal neurons in layers 4 and 5 of 
the primary motor cortex, and of cortical peptidergic and GABAergic interneurons70-71 is 
controversial,72 but loss of pyramidal cells and interneurons extends to cortical areas 4, 9 and 
24.  Loss of cortical pyramidal neurons and interneurons in distant, indirectly connected 
cortical areas is consistent with the notion that ALS and FTLD are related anterior brain 
degenerations,. Selective susceptibility of long axons, as a concept,73 has been superseded by 
the notion of vulnerability of functionally related neuronal and glial networks, associated 
with TDP43 deposits in remaining neurons. It is difficult to correlate clinical phenotype with 
motor or frontal cortical or CST pathology in ALS.63-66 Indeed, in progressive muscular 
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atrophy (PMA) despite little or no clinical evidence of UMN involvement there is almost 
universal pathological evidence of CST degeneration,74,75 perhaps clinically undetectable due 
to the extent of LMN loss and muscle atrophy.  
 
Overall, therefore, the pathological evidence points towards a process of axonal degeneration. 
Occasionally MRI reveals striking signal change in the cerebral CSTs76 but whether or not 
this represents Wallerian degeneration, a progressive anterograde degeneration of axons in 
reaction to injury, is unclear.77,782However, blocking the molecular pathways that contribute 
to Wallerian degeneration does not modulate neurodegeneration in mouse ALS models.79 
Neuronal cell bodies and axons in CNS motor pathways seem to be involved together..  
 
Intracellular inclusions containing ubiquitin, p62, and abnormal TDP-43 are far less marked 
in cortical motor neurons than in somatic motor neurons of the brain stem and spinal cord, or 
in neurons in layers 2, 3 and 5 in the prefrontal and temporal regions in FTLD and ALS-
FTLD. Altered TDP-43 probably drives degeneration in the CST. Abnormalities in Betz cells 
and pyramidal cells of the primary motor cortex in sporadic and familial ALS, and in ALS-
FTLD, include fragmentation, vacuolation, and atrophy of apical dendrites, loss of spines, 
apical dendrite retraction and loss of postsynaptic densities.80-83 Studies in animal models 
suggest that dendritic pathology is an early, indeed pre-symptomatic, feature of ALS84-86 and 
that TDP-43 cytoplasmic mislocalisation is associated with reduction in dendritic spine 
density.862How far these observations mirror the evolution of pathology in human ALS is 
uncertain.87 In summary, there is incomplete understanding of the dynamics of UMN 
degeneration in ALS.65 Genetic heterogeneity, and the wide variation in the distribution and 
burden of UMN pathology across the ALS and ALS-FTLD syndromes, suggests marked 
variability in the underlying dynamic processes, even in clinically similar ALS syndromes.88  
 
Structural biochemistry of the UMN in ALS 
Neurofilaments (NFs) are components of the neuronal cytoskeleton, classified by molecular 
weight into light chain (NfL), heavy chain (NfH) and intermediate chain. Raised CSF and 
blood levels have been demonstrated in many CNS diseases, correlated with the clinical 
intensity and presumably reflecting the rate of neuronal and axonal loss.89 In the earliest 
reports of raised CSF NF levels seen in ALS, it was noted that levels were highest in those 
with UMN signs.90,91 This was replicated in larger patient series, in which a strong 
relationship to rate of increasing disability was confirmed.92 The assumption that high CSF 
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levels in ALS reflect CST damage was tested using paired diffusion tensor imaging 
measures, but the results showed limited5 or no apparent association.93 Additional  CSF and 
blood-based studies have reported only weak distinction between NF levels and clinical 
UMN versus LMN involvement in ALS.94,95 
 
 
Imaging in ALS: widespread UMN abnormalities  
Macroscopic post mortem cerebral atrophy is strikingly limited in ALS. Localized, ‘knife-
edge’ atrophic pre-central gyri are seen in slowly progressive cases, especially in Primary 
Lateral Sclerosis, a syndrome in which degeneration is clinically limited to the UMN.96 
Automated volumetric MRI studies in ALS may detect diffuse frontal cerebral atrophy, 
especially associated with cognitive impairment97-99 but there is currently only limited 
evidence supporting somatotopic motor cortical atrophy in relation to regional motor 
disability.99,100 In some patients there is hyperintensity in the CSTs in T2-weighted MRI,101 
but with weak clinical correlation.102 However, T2-based MRI signal analysis, using 
diffusion tensor imaging (DTI), has confirmed consistent loss of CST integrity more 
consistently related to classic clinical UMN involvement.103Linkage of primary motor 
cortical atrophy and clinical UMN signs is strengthened by MR spectroscopy, using reduced 
N-acetylaspartate levels as a surrogate marker for neuronal loss, both in region-of-interest104 
and whole-brain studies.105 Interhemispheric motor cortical fibres in the central corpus 
callosum (Fig 1) are consistently involved in ALS,106,107,108 especially in PLS.109,110 DTI 
changes correlate with clinical and transcortical magnetic stimulation studies of UMN 
involvement.107,109,111 and Wallerian degeneration with microglial infiltration has been 
suggested as correlates of these white matter tract MRI changes.112,113 
 
White matter tract damage in ALS (Fig 1) is invariably bilateral in DTI studies and extends 
far beyond the pyramidal tracts and the corpus callosum, even in patients studied soon after 
the onset of focally restricted symptoms.114 Structural studies focused beyond the cortical 
grey matter in ALS have shown associated changes in basal ganglia,99 particularly in the 
thalami - points of integration with widespread frontotemporal cortical involvement in the 
course of the disease.115 MRI has confirmed the neuropathological finding that in progressive 
muscular atrophy (PMA) there is typically also sub-clinical degeneration of the pyramidal 
pathway.74,75 
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Neuroimaging markers and disability in ALS are poorly correlated, reflecting dependence of 
the ALS Functional Rating Scale on LMN loss.116 Functional brain imaging with positron 
emission tomography (PET), using radiotracers sensitive to glucose metabolism and blood 
flow has also demonstrated brain changes beyond primary motor regions.117,118 Blood flow 
PET during performance of a focused upper limb task revealed cortical activation extending 
to facial areas of the motor cortex, implying an alteration in local circuit neurophysiology, 
whether compensatory or a primary pathological process.119 Subsequent ligand PET studies 
using Flumazenil as a marker of GABAergic inhibitory receptors showed loss of binding in 
motor and premotor regions in ALS, but with relative preservation in familial slowly-
progressive ALS.120 Combined DTI and functional MRI studies provide limited support for a 
more direct role of inhibitory interneuron loss in the pathogenesis of ALS, rather than a 
solely compensatory process121 and MR spectroscopy has provided limited evidence for 
reduced GABA-ergic influence within the primary motor cortex.122 
 
Functional MRI based on regional patterns of synchronously fluctuating blood oxygenation 
level-dependent (BOLD) signal in the task-free, so-called resting state, has revealed a 
network-based dysfunction underlying neurodegenerative disorders more broadly, 123 but also 
to ALS.124 Resting state network abnormalities, in the form of increased functional 
connectivity, are detectable in asymptomatic carriers of penetrant ALS-causing genetic 
variants.125 Further, the unique temporal sensitivity of magnetoencephalography in 
demonstrating differences in beta-band cortical oscillations associated with the preparation, 
execution and recovery from motor activity126 promises to be potentially powerful for studies 
of corticomuscular coherence in analysing broader motor system ‘connectome’ dysfunction 
in ALS.127 
 
Neurophysiological studies of the UMN in ALS 
Early studies used transcranial electrical stimulation of the motor cortex.128 This induced 
depolarization of large pyramidal neurons, and showed absent or delayed cortical responses, 
confirming that the fast conducting UMN tract was damaged in this disorder.129-131 The 
central conduction time was found to be more frequently delayed in patients with UMN 
signs129 and this test was more sensitive than clinical assessment in the identification of UMN 
dysfunction.129-131 Transcranial magnetic stimulation132 (TMS), which superseded electrical 
brain stimulation, induces an intracortical current causing a transmembrane ionic flow that 
induces preferential transsynaptic excitation of pyramidal cells.133 Motor cortical dysfunction, 
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related to clinical findings, is detectable in ~70% of ALS patients,134 and in ~30% of those 
with pure LMN presentations.134,135 In addition, in early ALS the cortical motor threshold is 
reduced in strong muscles, in particular in those with fasciculations.134-138 Short interval 
intracortical  inhibition (SICI), 1-4ms, measured using a paired stimulus technique is 
mediated by GABA-ergic (GABA-A) interneuronal circuits, and is reduced in ALS.139,140 An 
automated cortical threshold tracking technique, recording decreased motor amplitude in the 
target muscle141 has shown that this is a consistent early marker of ALS, and that it precedes 
clinical onset in SOD1 familial ALS. Furthermore, this abnormality is partially normalized 
by riluzole.142 Peri-stimulus time histogram studies in early affected patients showed 
increased magnitude of EPSPs.143 Fasciculations, a typical marker of LMN dysfunction in 
ALS, can sometimes be evoked by TMS,144 probably representing LMN hyperexcitability.  
 
Spasticity, a feature of the classical UMN syndrome, is a sign of alpha-corticomotoneuronal 
hyperexcitability.39 This membrane change is associated with stable membrane potentials 
(plateau potentials), that resist changes in response to peripheral inputs,145 shown by 
analyzing the variability of the LMN firing rate in ALS and PLS.146 The cortical silent period 
(CSP), mainly representing cortical inhibition,147 is a period of EMG silence during muscle 
contraction following a motor response evoked by TMS. It tends to be shorter in ALS, 
especially early in disease progression.148 The H-reflex, mirroring the monosynaptic tendon-
reflex, is abnormal consistent with clinical signs of UMN involvement, especially in analyses 
of the slope angle of its earliest rising phase.149 These changes are consistent with coupled 
UMN-LMN hyperexcitability. However, adapted interneuronal responses in the spinal cord 
resulting from reduced corticospinal input, leading to increased compensatory alpha-
motoneuron hyperexcitability are also a possible mechanism.150 Hyperexcitability may be an 
early feature of neuronal degeneration but, also, a transitory adaptive process to compensate 
for neuronal loss, although the latter seems less likely.151,152 Current neurophysiological 
methods do not address function in most of the ancillary UMN pathways, as reviewed above, 
that have a critical role in the disease process. In addition, the role of spinal cord UMN 
pathways, an integral component of the CNS, is not well defined.  
 
Conclusions 
ALS is a disorder characterised by anterior brain neurodegeneration,  that seems to result 
from interactions between genetic and potential environmental risk factors, with striking 
clinical variability.88 Recognition of the UMN abnormality in ALS has always been difficult, 
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despite its importance for robust diagnosis.1,3,4 This reflects diagnostic emphasis on the 
classical clinical signs of internal capsular lesions as the epitome of the UMN syndrome. 
However, in ALS, frontal brain degeneration is widespread, with complex secondary efferent 
and commissural tract degenerations diffusely involving the brain motor network and its 
related connections. Involvement of other brain structures, including thalamic123 and 
cerebellar changes,153 and the anterior horns in the spinal cord,2 and frontal cognitive 
abnormalities, is consistent with this concept of anterior brain degeneration. In ALS and 
ALS-FTLD classical UMN features, as seen in focal brain lesions, are overwhelmed by 
anterior horn cell and interneuronal degeneration in the spinal cord,2 and by higher-order 
functional motor deficits.  The latter have been underestimated by ALS clinicians. Expansion 
of the concept of the UMN deficit in the ALS syndrome, including structural and functional 
brain imaging and neurophysiological assessment of cortical and deep white matter motor 
systems will facilitate understanding of the functional deficits. Given the pathophysiological 
complexity of the UMN syndrome it is not surprising that the full clinical syndrome is often 
not present in ALS, underlying the need for surrogate markers of UMN dysfunction. A wider 
concept of the UMN syndrome in ALS is required.  
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Table 1: Classical clinical features of upper and lower motor neuron syndromes 
Note that these traditional criteria do not include any higher-order functional tests in the case 
of UMN disorders, which could distinguish fronto-temporal cerebral dysfunction from 
limited lesions in the CSTs in the brainstem or spinal cord. Internal capsular lesions 
frequently involve non-corticospinal descending pathways, in addition to the corticospinal 
pathways themselves. 
 
Clinical sign UMN syndrome LMN syndrome 
weakness “pyramidal” distribution; i.e. 
hip flexor and foot 
dorsiflexor predominant 
focal or multifocal, often in 
peripheral nerve or root 
distribution 
loss of distal dexterity present absent if no sensory loss 
slowness and simplification 
of movement 
present absent 
poor balance responses present absent 
fatigue present present 
muscular atrophy slight or absent prominent in weak muscles 
muscular tone increased with spasticity reduced in weak muscles 
deep tendon and superficial 
reflexes 
tendon reflexes increased 
Superficial reflexes 
diminished 
tendon reflexes reduced or 
absent 
superficial reflexes normal 
or reduced 
Babinski response (and 
related responses) 
present absent 
fasciculation absent present 
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Fig 1: Diffusion Tensor Imaging (DTI) in ALS 
DTI is a non-invasive, in vivo application of MRI that is sensitive to a reduction in 
unidirectional water movement associated with the loss of large white matter tract integrity 
arising through a variety of brain pathologies. In ALS, there is a consistent reduction in a 
quantifiable metric known as fractional anisotropy, that is most consistently spatially 
localised to the caudal CST and interhemispheric motor fibres of the corpus callosum 
(marked on the images here in yellow and orange over the background DTI white matter tract 
skeleton, shown in green). 
 
 
 
 
 
 
 
 
 
